Results 141 to 150 of about 299,280 (207)

Oral Porphyromonas gingivalis and Fusobacterium nucleatum Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia. [PDF]

Biomedicines, 2022
Curia MC, Pignatelli P, D'Antonio DL, D'Ardes D, Olmastroni E, Scorpiglione L, Cipollone F, Catapano AL, Piattelli A, Bucci M, Magni P.   +10 more
europepmc   +1 more source

Glucose metabolism in heterozygous familial hypercholesterolemia with a founder effect and a high diabetes prevalence: a cross-sectional study. [PDF]

Cardiovasc Diabetol
González-Lleó AM, Brito-Casillas Y, Martín-Santana V, Gil-Quintana Y, Tugores A, Scicali R, Riaño M, Hernández-Baraza L, Jiménez-Monzón R, Girona J, Di Giacomo Barbagallo F, Masana L, Boronat M, Wägner AM, Sánchez-Hernández RM.   +14 more
europepmc   +1 more source

Myocardial fibrosis assessed by magnetic resonance imaging in asymptomatic heterozygous familial hypercholesterolemia: the cholcoeur study. [PDF]

EBioMedicine, 2021
Gallo A, Giral P, Rosenbaum D, Mattina A, Kilinc A, Giron A, Bouazizi K, Gueda Moussa M, Salem JE, Carrié A, Carreau V, Béliard S, Bittar R, Cluzel P, Bruckert E, Redheuil A, Kachenoura N.   +16 more
europepmc   +1 more source

Apparent Nonresponse to PCSK9 Inhibition in a Patient With Heterozygous Familial Hypercholesterolemia Due to PCSK9 Gene Duplication. [PDF]

JACC Case Rep
Pindwarawala M, Bose S, Brunham LR.
europepmc   +1 more source

Impact of a whole food, plant-based diet on LDL-cholesterol and cardiovascular risk factors in adults with heterozygous familial hypercholesterolemia: a randomized, two-period, two-treatment, crossover, fully controlled feeding trial. [PDF]

Nat Commun
Lessard-Lord J, Guay V, Rancourt-Bouchard M, Couture P, Gangloff A, Blais J, Tremblay AJ, Greffard K, Bilodeau JF, Rudkowska I, Drouin-Chartier JP.   +10 more
europepmc   +1 more source

Efficacy and outcomes of inclisiran in the management of homozygous and heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. [PDF]

Ann Med Surg (Lond)
Khan Z, Singh A, Haseeb Ur Rasool M, Qasim N, Yafaa Naveed Chaudhary M, Syed S, Riaz M, Rehman W, Rehman I, Islam R, Islam H, Muhammad A, Devi R, Wei CR, Naaz F, Akilimali A.   +15 more
europepmc   +1 more source

Echocardiographic Calcium Score of Aortic Valve Correlates with Coronary Artery Calcium Score in Heterozygous Familial Hypercholesterolemia. [PDF]

Life (Basel)
Cefalù AB, Nardi E, Giammanco A, Gagliardo CM, Barbagallo CM, La Grutta L, Toia P, Brucato F, Scrimali C, Fasciana TMG, Spina R, Lanza M, Vitale F, Noto D, Averna M.   +14 more
europepmc   +1 more source

<i>Proprotein Convertase Subtilisin</i>/<i>Kexin Type 9</i> (<i>PCSK9</i>) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]

Int J Mol Sci
Woźniak E, Woźniak A, Pawlos A, Broncel M, Satała J, Bukowska B, Gorzelak-Pabiś P.   +6 more
europepmc   +1 more source

Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia. [PDF]

Sci Rep
Woźniak E, Broncel M, Woźniak A, Satała J, Pawlos A, Bukowska B, Gorzelak-Pabiś P.   +6 more
europepmc   +1 more source

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

JAMA
Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL.   +11 more
europepmc   +1 more source